相关实验视频

Updated: Jun 9, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

蒂尔德拉基祖马布200毫克的有效性:意大利多中心研究

Annunziata Dattola¹, Nicoletta Bernardini², Francesca Svara¹

¹Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.

The Journal of dermatological treatment

|October 27, 2024

概括

提尔德拉基祖马布200毫克有效治疗中度至重度的牛皮,特别是在体重或疾病负担较高的患者中. 这种IL-23抑制剂显示显著的皮肤清除和改善生活质量,没有新的安全问题.

科学领域:

免疫皮肤学免疫皮肤学
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

牛皮是一种慢性免疫媒介疾病.
对于严重病例或体重较高的患者来说,治疗可能具有挑战性.
提尔德拉基祖马布是一种IL-23抑制剂,已被批准用于100mg的中度至重度牛皮.

研究的目的:

在中度至重度牛皮患者中评估tildrakizumab 200mg的疗效和安全性.
专注于高体重 (>90kg),高疾病严重程度 (PASI ≥20) 和难以治疗的患者亚组.
比较生物天真与生物经验丰富的患者的结果,以及两性之间的结果.

主要方法:

多中心,前性研究设计.
成年患者在第0周,第4周,然后每隔12周接受200毫克的皮下注射.
通过24周的PASI,DLQI,生殖器PASI和NAPSI得分来评估有效性.

主要成果:

平均PASI分数显著减少,从14.6降至0.4.4.
在24周内达到PASI 90 (100.0%) 和PASI 100 (80.3%) 的高率.
生活质量的明显改善 (DLQI从14.2到1.8) 和生殖器牛皮和指甲牛皮 (NAPSI) 的特定得分.

结论:

提尔德拉基祖马布200毫克是适度至重症牛皮的有效治疗方法.
对于体重较高,疾病负担较大,敏感区域受影响的患者来说,具有特别的益处.
200mg剂量显示出良好的安全性,没有发现新的不良事件.

关键词:

有效性有效性.这是一种抗IL2323的药物.牛皮是一种牛皮.这就是Tildrakizumab.提德拉基祖马布 200 毫克

更多相关视频

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...